6 Auguat 2020 - Covid-19 Test Manufacturing Partner

Avacta has announced that it has appointed BBI Solutions, part of BBI Group, to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cyvita. The agreement between the two companies has the potential to produce millions of tests a month and Avacta aims to begin clinical validation of the test as soon as possible. The company expects very high demand for these tests.  Although there is clearly a long way to go in developing the test, investors looking for a company involved in helping to fight . . .

This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.

Already a member, log in HERE.